. Data Presented at GTCbio's Oncology Biomarkers Conference
DURHAM, NC, and LIEGE, BELGIUM - January 26, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its partner, Predictive Biosciences, will present data from testing of a non-invasive bladder cancer diagnostic assay that incorporates two MDxHealth DNA methylation biomarkers, NID2 and TWIST.

Data being presented today by Predictive Biosciences at GTCbio's Oncology Biomarkers Conference in San Diego, USA demonstrates that the combination of four biomarkers (including protein, genetic and DNA methylation markers) in its CertNDxTM Bladder Cancer Assay resulted in 94 percent sensitivity, with a 99.5 percent negative predictive value (NPV), the probability that a patient who has tested negative for cancer is disease free. This urine based test is being developed as a tool to aid the clinical management of bladder cancer. In the clinic, patients who are tested and shown to be disease free may then be excluded from undergoing invasive procedures.

"Predictive Biosciences's approach of combining protein, genetic and DNA methylation markers into a single test is demonstrating very good results in bladder cancer and we are proud of the use of our NID2 and TWIST methylation markers in a much needed product that could help patients avoid unnecessary invasive tests," said Dr. Jan Groen, CEO of MDxHealth.